Page 128 - Read Online

Page 312 Ponnusamy et al. Cancer Drug Resist 2019;2:297-312 I http://dx.doi.org/10.20517/cdr.2018.11

activities. EMBO J 2012;31:110-23.
74. Cai J, Tian AX, Wang QS, Kong PZ, Du X, et al. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and
multidrug resistance of basal-like breast cancer. Cancer Lett 2015;367:129-37.
75. Fang X, Cai Y, Liu J, Wang Z, Wu Q, et al. Twist2 contributes to breast cancer progression by promoting an epithelial-mesenchymal
transition and cancer stem-like cell self-renewal. Oncogene 2011;30(47):4707-20.
76. Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences.
Stem Cells 2012;30:372-8.
77. Paranjape AN, Balaji SA, Mandal T, Krushik EV, Nagaraj P, et al. Bmi1 regulates self-renewal and epithelial to mesenchymal transition
in breast cancer cells through Nanog. BMC Cancer 2014;14:785.
78. Ponnusamy L, Mahalingaiah PKS, Chang YW, Singh KP. Reversal of epigenetic aberrations associated with the acquisition of
doxorubicin resistance restores drug sensitivity in breast cancer cells. Eur J Pharm Sci 2018;123:56-69.
79. Toh TB, Lim JJ, Chow EK. Epigenetics in cancer stem cells. Mol Cancer 2017;16:29.
80. Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer:
achieving the full therapeutic potential of HDACi. Front Oncol 2018;8:92.
81. Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol 2010;14:505-10.
82. Gomez-Casal R, Bhattacharya C, Epperly MW, Basse PH, Wang H, et al. The HSP90 inhibitor ganetespib radiosensitizes human lung
adenocarcinoma cells. Cancers (Basel) 2015;7:876-907.
83. Walsh LA, Damjanovski S. IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-beta1
resulting in epithelial to mesenchymal transition. Cell Commun Signal 2011;9:10.